{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:02:44Z","timestamp":1782741764260,"version":"3.54.5"},"reference-count":102,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive, benign neoplasm arising from the synovium of joints, tendon sheaths, and bursa. There are two main subtypes of TGCT: localized-type TGCT(L-TGCT) and diffuse-type TGCT (D-TGCT). While surgical excision is still considered the gold standard of treatment, the high recurrence rate, especially for D-TGCT, may suggest the need for other treatment modalities. Materials and Methods: This study reviews current literature on the current treatment modalities for refractory-relapsed TGCT disease. Results: The gold standard of treatment modality in TGCT remains surgical excision of the tumor nevertheless, the elevated recurrence rate and refractory disease, particularly in D-TGCT indicates and underscores the necessity for additional treatment alternatives. Conclusions: TGCT is a benign tumor with inflammatory features and a potential destructive and aggressive course that can lead to significant morbidity and functional impairment with a high impact on quality of life. Surgical resection remains the gold standard current treatment and the optimal surgical approach depends on the location and extent of the tumor. Systemic therapies have been recently used for relapsed mainly cases.<\/jats:p>","DOI":"10.3390\/medicina60101675","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T05:47:58Z","timestamp":1728884878000},"page":"1675","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment Modalities for Refractory-Recurrent Tenosynovial Giant Cell Tumor (TGCT): An Update"],"prefix":"10.3390","volume":"60","author":[{"given":"Vasiliki","family":"Dania","sequence":"first","affiliation":[{"name":"First Department of Orthopedic Surgery, School of Medicine, National and Kapodistrian University of Athens, \u201cATTIKON\u201d University General Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7481-2771","authenticated-orcid":false,"given":"Nikolaos A.","family":"Stavropoulos","sequence":"additional","affiliation":[{"name":"First Department of Orthopedic Surgery, School of Medicine, National and Kapodistrian University of Athens, \u201cATTIKON\u201d University General Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Gavriil","sequence":"additional","affiliation":[{"name":"First Department of Orthopedic Surgery, School of Medicine, National and Kapodistrian University of Athens, \u201cATTIKON\u201d University General Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4759-4814","authenticated-orcid":false,"given":"Ioannis","family":"Trikoupis","sequence":"additional","affiliation":[{"name":"First Department of Orthopedic Surgery, School of Medicine, National and Kapodistrian University of Athens, \u201cATTIKON\u201d University General Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-2720","authenticated-orcid":false,"given":"Panagiotis","family":"Koulouvaris","sequence":"additional","affiliation":[{"name":"First Department of Orthopedic Surgery, School of Medicine, National and Kapodistrian University of Athens, \u201cATTIKON\u201d University General Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0733-6565","authenticated-orcid":false,"given":"Olga D.","family":"Savvidou","sequence":"additional","affiliation":[{"name":"First Department of Orthopedic Surgery, School of Medicine, National and Kapodistrian University of Athens, \u201cATTIKON\u201d University General Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-0719","authenticated-orcid":false,"given":"Andreas F.","family":"Mavrogenis","sequence":"additional","affiliation":[{"name":"First Department of Orthopedic Surgery, School of Medicine, National and Kapodistrian University of Athens, \u201cATTIKON\u201d University General Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis J.","family":"Papagelopoulos","sequence":"additional","affiliation":[{"name":"First Department of Orthopedic Surgery, School of Medicine, National and Kapodistrian University of Athens, \u201cATTIKON\u201d University General Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"key":"ref_1","unstructured":"Fletcher, C.D.M.B.J., Hogendoorn, P.C.W., and Mertens, F. (2013). Tenosynovial giant cell tumour, localized type, WHO Classification of Tumours of Soft Tissue and Bone."},{"key":"ref_2","first-page":"731","article-title":"Pigmented: Villonodular synovitis, bursitis and tendosynovitis","volume":"31","author":"Jaffe","year":"1941","journal-title":"Arch. Pathol."},{"key":"ref_3","first-page":"185","article-title":"Cancer de la gaine des tendons","volume":"25","author":"Chassaignac","year":"1852","journal-title":"Gaz. Des Hop. Civ. Mil."},{"key":"ref_4","first-page":"335","article-title":"The pathogenesis and long-term end results of pigmented villonodular synovitis","volume":"114","author":"Granowitz","year":"1976","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102491","DOI":"10.1016\/j.ctrv.2022.102491","article-title":"Best clinical management of tenosynovial giant cell tumor (TGCT): A consensus paper from the community of experts","volume":"112","author":"Stacchiotti","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","unstructured":"De Saint Aubain Somerhausen, N., and van de Rijn, M. (2020). Tenosynovial Giant Cell Tumour, World Health Organization (WHO) Classification of Soft Tissue and Bone Tumours."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jcot.2017.06.014","article-title":"Giant cell tumour of tendon sheath and synovial membrane: A review of 26 cases","volume":"8","author":"Kant","year":"2017","journal-title":"J. Clin. Orthop. Trauma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.otsr.2016.11.002","article-title":"Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)","volume":"103","author":"Gouin","year":"2017","journal-title":"Orthop. Traumatol. Surg. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors. A nationwide study in the Netherlands","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3899\/jrheum.160816","article-title":"Tenosynovial Giant Cell Tumor: Incidence, prevalence, patient characteristics and recurrence. A registry-based cohort study in Denmark","volume":"44","author":"Ehrenstein","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13569-015-0030-2","article-title":"Metastating tenosynovial giant cell tumor, diffuse type\/pigmented villonodular synovitis","volume":"5","author":"Righi","year":"2015","journal-title":"Clin. Sarcoma Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/PAS.0b013e318158428f","article-title":"Malignant diffuse type tenosynovial giant cell tumors: A series of 7 cases comparing with 24 benign lesions with review of the literature","volume":"32","author":"Li","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Nakayama, R., Jagannathan, J.P., Ramaiya, N., Ferrone, M.L., Raut, C.P., Ready, J.E., Hornick, J.L., and Wagner, A.J. (2018). Clinical characyeristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor:initial experience of molecularity targeted therapy. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5188-6"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/rheumatology\/keu230","article-title":"Long term follow up results of primary and recurrent pigmented villonodular synovitis","volume":"53","author":"Verspoor","year":"2014","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.semarthrit.2010.07.005","article-title":"Pigmented Villonodular Synovitis: A retrospective single-Center study of 122 cases and review of the literature","volume":"40","author":"Ottaviani","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumor\/pigmented villonodular synovitis:outcome of 294 patients before the era of kinase inhibitors","volume":"51","author":"Palmerini","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s11999.0000000000000102","article-title":"Tenosynovial Giant Cell Tumors in Children: A Similar Entity Compared with Adults","volume":"476","author":"Mastboom","year":"2018","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_18","unstructured":"(2021, June 06). Available online: https:\/\/rarediseases.org\/rare-diseases\/tenosynovial-giant-cell-tumor\/."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00003086-198910000-00034","article-title":"Pigmented villonodular synovitis. A retrospective review of affected large joints","volume":"247","author":"Schwartz","year":"1989","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_20","unstructured":"(2024, April 12). Available online: https:\/\/emedicine.medscape.com\/article\/1253223-overview."},{"key":"ref_21","unstructured":"Gaillard, F. (2024, September 05). Pigmented Villonodular Synovitis (PVNS). Case Study. Available online: https:\/\/radiopaedia.org\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1148\/rg.285085134","article-title":"Pigmented villonodular synovitis: Radiologic-pathologic correlation","volume":"28","author":"Murphey","year":"2008","journal-title":"Radiographics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00167-018-4942-2","article-title":"Distinct extra-articular invasion patterns if diffuse pigmented villonodular synovitis","volume":"26","author":"Kim","year":"2018","journal-title":"Knee Surg. Sports Traumatol. Arthrosc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2214\/ajr.152.2.337","article-title":"Imaging of pigmented villonodular synovitis with emphasis on MR imaging","volume":"152","author":"Jelinek","year":"1989","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10067-003-0827-x","article-title":"MRI features of pigmented villonodular synovitis (PVNS)","volume":"23","author":"Cheng","year":"2004","journal-title":"Clin. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/jcp.54.5.404","article-title":"Giant cell tumour of tendon sheath(localized nodular tenosynovitis): Clinicopathological features of 71 cases","volume":"54","author":"Monaghan","year":"2001","journal-title":"J. Clin. Pethol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/his.13744","article-title":"Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?","volume":"74","author":"Mastboom","year":"2019","journal-title":"Histopathology"},{"key":"ref_28","first-page":"1383","article-title":"Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts","volume":"150","author":"Darling","year":"1997","journal-title":"Am. J Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00000478-200004000-00002","article-title":"Diffuse type giant cell tumor: Clinocopathologic and immunohistochemical analysis of 50 cases with extraarticular disease","volume":"24","author":"Fletcher","year":"2000","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/hupa.2003.52","article-title":"Cell characterization of mononuclear and giant cells constiuning pigmented villonodular synovitis","volume":"34","author":"Yoshida","year":"2003","journal-title":"Hum. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1302\/0301-620X.50B2.290","article-title":"The diagnosis and treatment of pigmented villonodular synovitis","volume":"50","author":"Byers","year":"1968","journal-title":"J. Bone Jt. Surg Br."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10573","DOI":"10.7150\/thno.48666","article-title":"Cadherin-11 cooperates with inflammatory factors to promote the migration and invasion of fibroblast-like synoviocytes in pigmented villonodular synovitis","volume":"10","author":"Cao","year":"2020","journal-title":"Theranostics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","article-title":"Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides","volume":"31","author":"Cupp","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/gcc.20501","article-title":"Panagopoulos I.Molecular identification of COL6A3-CSF1 fusion transcript in tenosynovial giant cell tumors","volume":"47","author":"Moller","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","article-title":"Diffuse-type tenosynovial giant cell tumor:Current treatments concepts and future perspectives","volume":"63","author":"Staals","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/gcc.22807","article-title":"Detection of csf1 rearrangements deleting the 3\u2019 UTR in tenosynovial giant cell tumors","volume":"59","author":"Ho","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_38","first-page":"26","article-title":"Cytokine and Matrix Metalloproteinase Expression in pigmented villonodular synovitis may mediate bone and cartilage destruction","volume":"18","author":"Rosier","year":"1998","journal-title":"Iowa Orthop. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.2937","article-title":"Osteoclast formation and function in pigmented villonodular synovitis","volume":"225","author":"Taylor","year":"2011","journal-title":"J. Pathol."},{"key":"ref_40","unstructured":"ScholarlyEditions (2023, August 30). Macrophages-Advances in Research and Application. Scholarly Editions. Available online: https:\/\/books.google.com.ec\/books?id=69qqQpFs3LUC."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/gcc.2870060404","article-title":"Chromosome aberrations in tenosynovial giant cell tumors and nontumorous synovial tissue","volume":"6","author":"Mertens","year":"1993","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/gcc.2870040312","article-title":"Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: Confirmation of trisomy 7 in uncultured cells","volume":"4","author":"Fletcher","year":"1992","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-4608(01)00488-5","article-title":"Analysis of the distribution and frequency of trisomy 7 in vivo in synovia from patients with osteoarthritis and pigmented villonodular synovitis","volume":"131","author":"Broberg","year":"2001","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.5858\/2000-124-1636-MGCTOS","article-title":"Malignant giant cell tumor of synovium (malignant pigmented villonodular synovitis)","volume":"124","author":"Layfield","year":"2000","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jso.23220","article-title":"A Multidisciplinary approach to giant cell of tendon sheath and synovium-a critical Appraisal of Literature and treatment proposal","volume":"107","author":"Gibbons","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2106\/JBJS.18.01147","article-title":"Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints: A Study Based on a Multicenter-Pooled Database of 31 International Sarcoma Centers","volume":"101","author":"Mastboom","year":"2019","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11999-012-2589-8","article-title":"Does combined open and arthroscopic synovectomy for diffuse PVNS of the knee improve recurrence rates?","volume":"471","author":"Colman","year":"2013","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0035-1040(06)75830-5","article-title":"Prise en charge de la synovite villonodulaire h\u00e9mopigment\u00e9e du genou et de ses r\u00e9cidives: \u00c0 partir d\u2019une s\u00e9rie r\u00e9trospective de 28 cas [Surgical management of pigmented villonodular synovitis of the knee: Retrospective analysis of 28 cases]","volume":"92","author":"Pinaroli","year":"2006","journal-title":"Rev. Chir. Orthop. Reparatrice Appar. Mot."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant cell tumors: An international, retrospective, cohort study","volume":"20","author":"Mastboom","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.knee.2017.04.019","article-title":"Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis","volume":"24","author":"Houdek","year":"2017","journal-title":"Knee"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.arth.2017.12.030","article-title":"Long term outcome of hip arthroplasty in the setting of pigmented villonodular synovitis","volume":"33","author":"Tibbo","year":"2018","journal-title":"J. Arthroplast."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/jars.2001.24068","article-title":"Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee","volume":"17","author":"Blanco","year":"2001","journal-title":"Arthroscopy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0360-3016(95)00514-Y","article-title":"Outcome following radiation treatment for high-risk pigmented villonodular synovitis","volume":"32","author":"Cummings","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijrobp.2008.10.058","article-title":"External beam radiation therapy enhances local control in pigmented villonodular synovitis","volume":"75","author":"Horoschak","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.ijrobp.2006.10.016","article-title":"External beam radiotherapy as postoperative treatment of diffuse pigmented villonodular synovitis","volume":"67","author":"Berger","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2009.07.1747","article-title":"Radiation therapy for treatment of pigmented villonodular synovitis: Results of a national patterns of care study","volume":"78","author":"Heyd","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jbspin.2010.02.010","article-title":"Complications following radiosynoviorthesis in osteoarthritis and arthroplasty: Osteonecrosis and intra-articular infection","volume":"77","author":"Kisielinski","year":"2010","journal-title":"Jt. Bone Spine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00402-018-3097-4","article-title":"The effects of the radiosynoviorthesis in pigmented villonodular synovitis of the knee","volume":"139","author":"Durr","year":"2019","journal-title":"Arch. Orthop. Trauma Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinb versus placebo for advanced tenosynovial cell tumour (ENLIVEN): A randomized phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2217\/fon-2020-0542","article-title":"Pexidartinib: First approved systemic therapy for patients with tenosynovial giant cell tumor","volume":"16","author":"Gelderblom","year":"2020","journal-title":"Future Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.33312","article-title":"Long-term outcomes of pexidartinib in tenosynovial giant cell tumors","volume":"127","author":"Gelderblom","year":"2021","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17453674.2021.1922161","article-title":"Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: Results from the ENLIVEN randomised clinical trial","volume":"92","author":"Tap","year":"2021","journal-title":"Acta Orthop."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/onco.13629","article-title":"Pexidartinib long term hepatic profile in patients with tenosynovial giant cell tumors","volume":"26","author":"Lewis","year":"2021","journal-title":"Oncologist"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.onc.1209007","article-title":"FMS receptor for M-CSF is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance","volume":"25","author":"Taylor","year":"2006","journal-title":"Oncogene"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/annonc\/mdn033","article-title":"Complete resonse to imatinib in relapsing pigmented villonoular synovitis\/tenosynovial giant cell tumor","volume":"19","author":"Blay","year":"2008","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of loccaly adnvanced. and\/or metastatic tenosynovial giant cell tumour\/pigmented villonodular synovitis","volume":"118","author":"Cassier","year":"2012","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2045-3329-3-8","article-title":"Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib","volume":"3","author":"Stacchiotti","year":"2013","journal-title":"Clin. Sarcoma Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Verspoor, F.G.M., Mastboom, M.J.L., Hannink, G., Maki, R.G., Wagner, A., Bompas, E., Desai, J., Italiano, A., Seddon, B.M., and van der Graaf, W.T.A. (2019). Long-Term Efficacy of Imatinib Mesylate in Patients with Advanced Tenosynovial Giant Cell Tumor. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-51211-y"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.suronc.2020.08.030","article-title":"The Effect of Imatinib Mesylate in Diffuse-Type Tenosynovial Giant Cell Tumours on MR Imaging and PET-CT","volume":"35","author":"Mastboom","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: A novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: A multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.06.028","article-title":"Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours","volume":"173","author":"Spierenburg","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1158\/1538-7445.AM2016-4889","article-title":"Abstract 4889: The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models","volume":"76","author":"Smith","year":"2016","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/1535-7163.MCT-21-0361","article-title":"Vimseltinib: A precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages","volume":"20","author":"Smith","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S1233","DOI":"10.1016\/j.annonc.2021.08.275","article-title":"1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)","volume":"32","author":"Gelderblom","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/fon-2023-0238","article-title":"The MOTION study: A randomized, Phase III study of Vimseltinib for the treatment of tenosynovial giant cell tumour","volume":"20","author":"Tap","year":"2023","journal-title":"Future Oncol."},{"key":"ref_78","unstructured":"(2023, November 16). Available online: https:\/\/www.onclive.com\/view\/vimseltinib-improves-25-week-orr-vs-placebo-in-tgct."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: A dose-escalation and dose-expansion phase 1 study","volume":"16","author":"Cassier","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","article-title":"Long term clinical activity, safety and patient-reported quality of life for emactuzumab treated patients with diffuse type tenosynovial giant cell tumor","volume":"141","author":"Cassier","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cpt.1964","article-title":"PK\/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients with Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor","volume":"108","author":"Smart","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"11078","DOI":"10.1200\/JCO.2017.35.15_suppl.11078","article-title":"A phase I\/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS)","volume":"35","author":"Sankhala","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_84","unstructured":"Cheng, E.Y., Kudlidjian, A., Block, J.A., Gitelis, S., Henshaw, R.M., Wilky, B.A., Trent, J.C., Abraham, J.A., Schramm, U., and Pinot, P. (2015, January 6\u201310). MCS110, an Anti-CSF-1 Antibody, for the Treatment of Pigmented Villonodular Synovitis (PVNS). Proceedings of the ISOLS\/MSTS 2015 Annual Meeting, Abstract, Orlando, FL, USA."},{"key":"ref_85","unstructured":"(2023, October 29). MCS110 in Patients with Pigmented Villonodular Synovitis (PVNS). ClinicalTrials.gov. IDNCT01643850, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01643850?tab=results."},{"key":"ref_86","unstructured":"(2023, December 15). Available online: https:\/\/www.creativebiolabs.net\/lacnotuzumab-overview.htm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1200\/JCO.2023.41.16_suppl.11559","article-title":"Efficacy and safety profile of pimicotinib (ABSK021) in Tenosynovial Giant Cell Tumor (TGCT): Phase 1b update","volume":"41","author":"Yao","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s13577-022-00823-0","article-title":"Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis","volume":"36","author":"Thongchot","year":"2022","journal-title":"Hum. Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5114\/reum.2021.110601","article-title":"Is intra articular infliximab therapy a good alternative to radionuclide synovectomy for a patient with refractory pigmented villonodular synovitis?","volume":"59","author":"Chojnowski","year":"2021","journal-title":"Rheumatologia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2005.11.006","article-title":"Colony-stimulating factor-1 in immunity and inflammation","volume":"18","author":"Chitu","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/0008-5472.CAN-06-2295","article-title":"Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway","volume":"67","author":"Zins","year":"2007","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/ard.2004.025692","article-title":"Tumour necrosis factor a blockade in treatment resistant pigmented villonodular synovitis","volume":"64","author":"Kroot","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/1756-185X.12585","article-title":"Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of infliximab:a case series and review of the literature","volume":"18","author":"Praino","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00296-009-1185-z","article-title":"Intra-articular adalimumab in a patient with pigmented villonodular synovitis","volume":"31","author":"Kobak","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4081\/reumatismo.2006.268","article-title":"Intra-articular etanercept treatment for severe diffuse pigmented villonodular knee synovitis","volume":"58","author":"Fiocco","year":"2011","journal-title":"Reumatismo"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.4049\/jimmunol.171.5.2637","article-title":"M-CSF induces vascular enthothelial growth factor production and angiogenic acticity from human monocytes","volume":"171","author":"Eubank","year":"2003","journal-title":"J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Curry, J.M., Eubank, T.D., Roberts, R.D., Wang, Y., Pore, N., Maity, A., and Marsh, C.B. (2008). M-CSF signals through the MAPK\/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003405"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/annrheumdis-2013-204589","article-title":"Efficacy of intra- articular bevacizumab for relapsing diffuse-type giant cell tumour","volume":"73","author":"Nissen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_99","unstructured":"(2023, December 15). Available online: https:\/\/www.tgctsupport.org\/amb-05x.html."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1101\/gad.948702","article-title":"C\/EBPalpha induces adipogenesis through PPARgamma: A unified pathway","volume":"16","author":"Rosen","year":"2002","journal-title":"Genes Dev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/jpet.302.1.18","article-title":"Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells","volume":"302","author":"Yamazaki","year":"2002","journal-title":"J. Pharmachol. Exp."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Takeuchi, A., Nomura, A., Yamamoto, N., Hayashi, K., Igarashi, K., Tandai, S., Kawai, A., Matsumine, A., Miwa, S., and Nishida, Y. (2019). Randomized Placebo-Controlled Double-Blind Phase II Study of Zaltoprofen for Patients with Diffuse-Type and Unresectable Localized Tenosynovial Giant Cell Tumors: A Study Protocol. BMC Musculoskelet. Disord., 20.","DOI":"10.1186\/s12891-019-2453-z"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/10\/1675\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:12:00Z","timestamp":1760112720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/10\/1675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":102,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["medicina60101675"],"URL":"https:\/\/doi.org\/10.3390\/medicina60101675","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]}}}